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IFN-g
1 T cell subsets accumulated specifically in the inflamed terminal ileum of CD patients. These cells had higher expression of Ki-67 and were active cytokine producers. In addition, their proportions within both the IL-17A-producer and IL-22-producer populations were increased significantly. These data suggest that IL-17A 
Introduction
Crohn's disease is a chronic inflammatory disease of the human intestine, the pathogenesis of which is not completely understood [1] . Accumulating evidence indicates that dysregulated mucosal immune responses towards the commensal microbiota contribute to this process and lead to tissue damage [2] . In CD patients, various components of the gut immune system are dysregulated, especially the abnormal T cell activity along with excess cytokine production. This may be the result of disruption of a negative regulatory mechanism. Traditionally, interferon (IFN)-g-producing T helper type 1 (Th1) cells are believed to be the major effector cells in the pathogenesis of CD [3] . Several lines of evidence also suggest that interleukin (IL)-17A-producing Th17 cells contribute to intestinal inflammation [4] [5] [6] . However, reports from clinical trials were surprising, as the anti-IFNg antibody fontolizumab resulted in only minor improvement of inflammation in CD patients [7] , and the anti-IL-17A antibody secukinumab was less effective than placebo in patients with moderate to severe CD [8] . However, the trial with the anti-IL-12/23-p40 antibody ustekinumab, that targeted cytokines that drive both Th1 and Th17 differentiation, reported significantly increased response rates in patients with moderate to severe CD [9] . These differential results from clinical trials of CD patients demonstrate that a strategy that targets both the Th1 and Th17 pathways might be more promising.
Innate lymphoid cells (ILCs) are newly identified innate effector cells that are prevalent in mucosal tissues, such as the gastrointestinal tract. They are divided into three groups (ILC1s, ILC2s and ILC3s), based on their cytokine production and transcription factor expression. In the normal gut, ILC3s are the most abundant ILC subset at steady state (approximately 60-75% of total ILCs) and play essential roles in host defence, regulation of inflammation, tissue repair and maintenance of epithelial barrier function [10] [14] [15] [16] . This phenotype change possibly results in immunopathology. Thus, in this study, we evaluated the alteration of both phenotype and function of mucosal ILC3s and the composition and features of effector T cells that produced IFN-g, IL-17A and/or IL-22 in the inflamed terminal ileum of CD patients. This effort will help us to explore a potential missing link between innate immunity and adaptive immunity and have a clearer understanding for the pathogenesis of CD.
Materials and methods
Subjects
Fresh terminal ileum surgical tissues were obtained from UF Health Shands Hospital (Gainesville, FL, USA), with the assistance of the UF Clinical and Translational Science Institute. All experiments were performed according to University of Florida Institutional Review Board-approved protocol, with written informed consent from all subjects. Twenty CD patients who responded poorly to various medications, developed intestinal complications and needed surgery therapy were included into this study. Their clinical characteristics are listed in Table 1 .
Tissue collection and processing
After the surgery, pathologists from the UF Health Shands Hospital performed gross examination of the surgical samples from CD patients, cut one piece of macroscopically unaffected terminal ileum (if available) or affected terminal ileum and passed the tissue to us. The range of collected tissue amounts was between 2Á0 and 8Á0 g. The time of tissue harvest after surgery is 1 h, on average. Harvested surgical ileum tissue was placed into stripping buffer [Mg 21 and Ca
21
-free Hanks's balanced salt solution (HBSS) media containing 100 U/ml penicillin, 100 mg/ml streptomycin, 25 mg/ml gentamycin and 0Á5 mM dithiothreitol (DTT)], delivered to the laboratory on ice. The outer fat tissue was removed immediately, 0Á3 g of tissue was put into a 1Á5-ml collection tube with 1 ml of RNAlater buffer (Thermo Fisher Scientific, Grand Island, NY, USA) for RNA extraction and 0Á3 g of tissue was fixed in 10% neutral-buffered formalin (Thermo Fisher Scientific, Grand Island, NY, USA) for histology evaluation. The residual tissue was cut into small strips, placed into 25-ml stripping buffer (as described above) and washed twice at 378C in the shaker for 10 min at a constant speed of 8 g. The supernatant was discarded. The remaining tissue was then minced further with a sterile surgical scalpel and digested in 25 ml digestion buffer [Dulbecco's modified Eagle's medium (DMEM) without sodium pyruvate supplemented with 75 U/ml collagenase type XI, 20 mg/ml Dispase neutral protease II, 500 U/ml DNase, 0Á5mM DTT and 1% fetal bovine serum (FBS)] at 378C in the shaker for 15 min at a constant speed of 8 g. The tissue was filtered through a 70-mm cell strainer, again dissociated mechanically on top of the strainer, and digested in 25-ml digestion buffer for another 15 min. The supernatant was collected and centrifuged at 287 g for 8 min. All cells were cryopreserved slowly in cell freezing medium (GIBCO, Grand Island, NY, USA) and transferred to liquid nitrogen for future side-by-side analysis.
Flow cytometry
After thawing, single-cell suspensions were incubated with LIVE/DEAD TM Fixable Yellow dye (Thermo Fisher Scientific) on ice for 30 min, then stained with antibodies to the following markers [all antibodies were from BioLegend (San Diego, CA, USA) unless stated otherwise]: antihuman Lineage Cocktail 3 (CD3, clone SK7; CD19, clone SJ25C1; CD20, clone L27 and CD14, clone MuP9; BD Bioscience), anti-CD45 (clone HI30; Thermo Fisher Scientific), anti-CD56 (clone HCD56), anti-CD117 (clone 104D2; eBioscience, San Diego, CA, USA), anti-CD127 (clone eBioRDR5; eBioscience), anti-NKp44 (clone P44-8), anti-CRTH2 (clone BM16), anti-CCR6 (clone G034E3), anti-human leucocyte antigen D-related (HLA-DR) (clone LN3), anti-CD80 (clone L307.4) and anti-CD86 (clone 2331). For intracellular staining, cells were fixed and permeabilized using the FIX & PERM V R Cell Permeabilization Kit (Thermo Fisher Scientific) and stained with anti-Ki-67(clone Ki-67). For cytokine production analysis, cells were stimulated with 200 ng/ml phorbol 12-myristate 13-acetate (Sigma-Aldrich, St Louis, MO, USA), 1 mg/ml ionomycin (Sigma-Aldrich) and 1 ml/ml monensin (Biolegend, San Diego, CA, USA) for 4Á5 h at 378C in a 5% CO 2 incubator, stained with surface markers, fixed and permeabilized as described above, and stained with anti-IFN-g (clone 4S.B3), anti-IL-17A (clone BL168) or anti-IL-22 (clone 22URTI). Data were acquired on a LSRII (BD Biosciences) in the Cytometry Core at the University of Florida, and analysed using FlowJo software version 9.8.1 (TreeStar Inc., Ashland, OR, USA).
Reverse transcription-polymerase chain reaction (RT-PCR)
A 0Á3-g sample of terminal ileum tissue was minced into small pieces and disrupted with the tissue homogenizer. Total RNA was isolated using QIAzol Lysis reagent (Qiagen, Valencia, CA, USA), following the manufacturer's instructions. The SuperScript V R VILO cDNA Synthesis Kit (Thermo Fisher Scientific) was used for cDNA synthesis. PCR was performed using an ABI PRISM StepOnePlus Real time PCR System (Thermo Fisher Scientific) in a 20-ml volume containing the cDNA, 2 3 TaqMan V R Gene Expression Master Mix, nuclease-free water and 13 Taqman Gene Expression Assay for target genes including Tbox transcription factor (TBX21), RAR-related orphan receptor C (RORC), IFN-g, IL-17A, IL-22, IL-12, IL-23 and tumour necrosis factor (TNF)-a (Thermo Fisher Scientific). Reactions were run in triplicate in three independent experiments. The mean of housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control to normalize target gene expression levels.
Histology
Fresh surgical intestinal tissue samples were fixed in formalin for 20 h at 48C, embedded in paraffin, sectioned and stained with haematoxylin and eosin for inflammation evaluation.
Statistical analyses
Statistical significance was determined using the MannWhitney U-test and Student's t-test, which were performed using GraphPad Prism version 6 software (GraphPad Software, La Jolla, CA, USA). As shown in the figures, the asterisk (*) levels indicate significant differences (*P-value < 0Á05, **P < 0Á01 and ***P < 0Á001).
Results
Dysregulated inflammatory gene expression in the inflamed terminal ileum of CD patients
We collected samples of inflamed and unaffected (when available) terminal ileum resections from 20 adult CD patients who failed medical treatment and developed intestinal complications (Table 1) . When compared to the unaffected ileums, the inflamed ileums presented with histological signs of intestinal inflammation, including epithelial monolayer damage, crypt architectural distortion and increased lymphocyte infiltration in the lamina propria (Fig. 1a) . As a further assessment of the inflammation, we compared the expression patterns of inflammatory genes within these tissues. The mRNA gene expression of proinflammatory cytokines IFN-g, IL-17A, IL-22, IL-1b, IL-23A, IL-12p35 and TNF-a, as well as transcription factor TBX21, were increased significantly in the inflamed terminal ileum of CD patients (Fig. 1b) .
There was no difference regarding the mRNA gene expression of transcription factor RORC (Fig. 1b) . Moreover, the mRNA expression ratios of TBX21/RORC and IFN-g/IL-17A were increased significantly in the inflamed tissues, while there was a trend towards elevations in the ratio of IFN-g/IL-22 (Fig. 1c) . Statistical analyses were performed using a two-tailed Mann-Whitney U-test. *P < 0Á05; **P < 0Á01.
Enrichment of IL-17A
1 IFN-g 1 and IL-22
subsets in the inflamed gut
Lamina propria mononuclear cells (LPMC) were also isolated from the surgical tissues and the profile of each T cell subset was investigated. It is important to note that our anti-IL-17A and anti-IL-22 antibodies were in the same channel.
Therefore, when we performed intracellular cytokine staining, only the combinations of anti-IFN-g and IL-17A antibodies or anti-IFN-g and IL-22 antibodies were used. In the CD45 1 lineage 1 compartment, the total number of isolated living lymphocytes per gram of tissue was significantly higher in the inflamed terminal ileum (Fig. 2a) . Consistent with inflamed terminal ileum (n 5 10). Statistical analyses were performed using a two-tailed Mann-Whitney U-test. *P < 0Á05; **P < 0Á01. (Fig. 2b,c) [5, 17] . Surprisingly, the frequency of the IL-17A 1 IFN-g -T cell subset within CD45 1 lineage 1 LPMC was comparable between inflamed tissues and unaffected tissues (Fig. 2b,c) . A trend in reduced frequency of the IL-22 1 IFN-g -T cell subset was observed in the inflamed terminal ileum of CD patients (Fig.  2b,c) . Interestingly, the frequencies of IL-17A
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1 IFN-g 1 and
IL-22
1 IFN-g 1 T cell subsets were up-regulated significantly in the inflamed tissues (Fig. 2b,c) Fig. 3a,b ). In addition, we evaluated the expression of homing receptor CCR6 on these populations. CCR6 is important for Th17 cell migration in the gut and is part of the Th17 cell signature [18] . (Fig. 3c,d ).
The alteration of ILC3s phenotype and function in the inflamed terminal ileum of CD patients
Emerging evidence demonstrates that ILCs are important innate effector and regulatory cells in tissue defence, along with the repair and maintenance of homeostasis, especially along the mucosal surfaces [19] . In the context of intestinal inflammation in CD patients, Bernink et al. showed previously that IFN-g-producing ILC1s accumulated in inflamed mucosal tissues [14] . However, their study included only seven patients. A relatively large cohort of CD patients would be helpful to evaluate and confirm further the reported changes of ILC phenotype and function in the gut of CD patients.
In the present study, we recruited 20 patients. The gating strategy used for our analysis is outlined in Fig. 4a . The numbers of total ILCs isolated per gram of tissue were comparable between groups (Fig. 4c ). In the unaffected terminal ileum, NKp44 1 ILC3s were the dominant ILC subset,
and comprised approximately 60% of the total ILCs (Fig.  4b,c) . These cells were potent IL-22 producers, but did not produce IL-17A and IFN-g (Fig. 4d) . However, in the inflamed tissue, the frequency of NKp44 ILC3s was reduced and the remaining ILC3s produced less IL-22 (Fig. 4d,e) . At the same time, we noticed that NKp44 1 ILC3s from the inflamed terminal ileum were also able to produce low amounts of IFN-g, but not IL-17A (Fig. 4d-f) . Additionally, the frequency of NKp44 -CD117 -ILC1s increased in the inflamed tissue (Fig. 4b,c) , along with the elevated frequency of IFN-g-producing cells within ILC1s. We also noticed that ILC1s from both unaffected tissues and inflamed tissues did not produce IL-22 ( Fig. 4g-i In addition to their role in the first line of defence against invading pathogens through rapid cytokine production, it has been suggested that ILCs can also influence adaptive immune responses, particularly those of effector T cells [20] . In mouse models, it was shown that ILC3-intrinsic MHC-II expression restrained pathogenic CD4
1 T cell responses specific for commensal gastrointestinal bacteria [12] . In our cohort, the frequencies of NKp44 ILC3s did not express the two classical co-stimulatory molecules CD80 and CD86 (Fig. 5b,c ) [12, 13] . Interestingly, the frequency of HLA-DR-expressing ILC3s was decreased significantly in the inflamed tissue compared to the unaffected area (Fig. 5c,d ). Together these data may suggest that NKp44 In the adaptive immunity compartment, it is well accepted that the IFN-g-producing T cells contribute to the intestinal inflammation in CD patients. However, it has been somewhat controversial regarding the role of IL-17A-producing cells in this process [21, 22] . Here, our data provide further evidence for a preferential skewing of T cells towards a dual IL-17A
1 IFN-g 1 or IL-22
type during active intestinal inflammation in CD patients. Our study also confirmed that the proinflammatory cytokines IL-12, IL-23 and IL-1b, which play key roles in the skewing of T cells, were expressed highly in the inflamed tissues [23] [24] [25] . This could partially explain the positive results from the latest Phase 3 clinical trial of ustekinumab (the monoclonal antibody to the IL-12/IL-23 p40 subunit) among patients with moderately to severely active CD [26] . In the Phase 2b trial mentioned earlier, ustekinumab treatment showed a benefit in terms of clinical response but not remission [9] . In this 2016 trial, subcutaneous ustekinumab maintained remission in patients [26] .
Regarding the polyfunctional T cells, there are some indications that they are superior in initiating active immune response and inflammation. Seder et al. argued . Statistical analyses were performed using Student's t-test. *P < 0Á05; **P < 0Á01. that polyfunctional T cells were associated with enhanced protection and were optimized for effector function for vaccine design [27] . Kannanqanat et al. showed that multiple-cytokine-producing anti-viral CD4 T cells were functionally superior to single-cytokine-producing cells [28] . Boyd et al. reported that pathogen-specific T cell . Statistical analyses were performed using a two-tailed Mann-Whitney U-test. *P < 0Á05; **P < 0Á01.
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polyfunctionality correlated with T cell efficacy and immune protection [29] . In the context of the intestinal inflammation of CD patients, their polyfunctionality could be detrimental. 
CD4
1 T cells in the inflamed colon of CD patients [31] . Similarly, we showed the enrichment of IL-17A
1 IFN-g 1 and IL-22 1 
IFN-g
1 T cell subsets in the inflamed terminal ileum. One of the limitations in our study was that our anti-IL- ILC3s provides evidence of type 1 skewing of innate lymphocytes during CD, which was supported further by the increased frequency of IFN-g-producing ILC1s in the inflamed tissues. It is important to note that the lineage marker antibody in our study for ILC phenotyping is limited in that it contains only CD3, CD14, CD19 and CD20, which makes it possible that there was potential contamination in our ILC1s by other cells.
Aside from their effector functions, multiple lines of evidence suggest a role for ILC3s in the regulation of adaptive immune responses, especially the CD4 1 T cell response towards commensal antigens in the gut [12, [35] [36] [37] . Our study demonstrated a direct correlation between the changes in NKp44 resided in the interfollicular region and the interface between B and T cell zones in the lymph node [36] . Those are the specific regions that lymphocytes traverse during various stages of adaptive immune responses. Mackley et al. revealed further that constitutive trafficking of RORgt 1 ILC3s from the intestine to the draining mesenteric lymph nodes was CCR7-dependent [37] . Imaging studies of ILC3s' location and traffic in the human intestine are needed urgently and would be extremely helpful in the understanding of the potential cellular interactions between ILC3s and other mucosal immune cells.
In conclusion, our data highlight the relative pathogenic role of IL-17A subset in the human gut might deserve more attention.
